

Fabrizio Cantini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5777390/fabrizio-cantini-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

2,002
citations

24
h-index

44
g-index

54
ext. papers

2,438
ext. citations

6.9
avg, IF

5.43
L-index

#	Paper	IF	Citations
52	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. <i>Journal of Infection</i> , 2021 , 82, 58-66	18.9	25
51	COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study. <i>Joint Bone Spine</i> , 2021 , 88, 105131	2.9	7
50	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 286.e7-286.e13	9.5	49
49	Immune Response in Patients With Immune-Mediated Inflammatory Disease. <i>Frontiers in Immunology</i> , 2021 , 12, 716857	8.4	1
48	Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements.. <i>Expert Opinion on Drug Safety</i> , 2021 , 1-11	4.1	0
47	Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data. <i>Therapeutics and Clinical Risk Management</i> , 2020 , 16, 287-297	2.9	4
46	Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 861-872	4.1	9
45	Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. <i>Journal of Infection</i> , 2020 , 81, 647-679	18.9	107
44	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. <i>Journal of Infection</i> , 2020 , 81, 318-356	18.9	274
43	The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 69-82	4.1	7
42	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. <i>Drugs</i> , 2020 , 80, 1929-1946	11.4	45
41	Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e13	2.4	6
40	The Nocebo Effect in Rheumatology: An Unexplored Issue. <i>Israel Medical Association Journal</i> , 2020 , 22, 185-190	0.9	
39	Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1444-1446	2.4	6
38	Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 415-425	4.1	15
37	Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. <i>Journal of Infection</i> , 2019 , 79, 15-23	18.9	9
36	Non-medical switching: save today and pay tomorrow. <i>Journal of Medical Economics</i> , 2019 , 22, 1160-1161	1.4	3

35	Biosimilars for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1195-1203	5.2	1
34	Additional comment to: Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? By Scherlinger and Schaeferbeke. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e25	2.4	4
33	Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e23	2.4	22
32	Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 2097-2111	2.9	2
31	Focus on biosimilar etanercept - bioequivalence and interchangeability. <i>Biologics: Targets and Therapy</i> , 2018 , 12, 87-95	4.4	11
30	Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 501-512	5.5	38
29	Case-control Study on Dactylitis, Enthesitis, and Anterior Uveitis in Spondyloarthritis Associated with Inflammatory Bowel Diseases: Role of Coexistent Psoriasis. <i>Journal of Rheumatology</i> , 2017 , 44, 1341-1346	4.1	11
28	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 183-192	5.3	53
27	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. <i>Mediators of Inflammation</i> , 2017 , 2017, 8909834	4.3	66
26	Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet disease after switching from infliximab originator. <i>European Journal of Rheumatology</i> , 2017 , 4, 288-290	1.7	14
25	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , 2016 , 35, 1281-6	3.9	72
24	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 519-32	5.3	41
23	Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. <i>International Journal of Rheumatic Diseases</i> , 2016 , 19, 799-805	2.3	13
22	Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 55-61	4.1	14
21	Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 35-54	4.1	53
20	Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 11-34	4.1	161
19	Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. <i>Autoimmunity Reviews</i> , 2015 , 14, 503-9	13.6	107
18	Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 146	2.8	1

17	Uveitis in Spondyloarthritis: An Overview. <i>Journal of rheumatology Supplement, The</i> , 2015 , 93, 27-9		23
16	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015 , 14, 864-74	13.6	22
15	Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence. <i>Journal of rheumatology Supplement, The</i> , 2014 , 91, 1-3		8
14	Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. <i>Journal of rheumatology Supplement, The</i> , 2014 , 91, 47-55		79
13	Tuberculosis risk in patients treated with non-anti-tumor necrosis factor- α targeted biologics and recently licensed TNF- α inhibitors: data from clinical trials and national registries. <i>Journal of rheumatology Supplement, The</i> , 2014 , 91, 56-64		63
12	Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. <i>Journal of rheumatology Supplement, The</i> , 2014 , 91, 41-6		47
11	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014 , 13, 822-30	13.6	63
10	Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. <i>Journal of rheumatology Supplement, The</i> , 2014 , 91, 78-82		11
9	HBV Reactivation in Patients Treated with Antitumor Necrosis Factor- α (TNF- α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. <i>International Journal of Rheumatology</i> , 2014 , 2014, 926836	2	45
8	Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013 , 65, 94-100	4.7	137
7	Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. <i>International Journal of Rheumatic Diseases</i> , 2012 , 15, 414-8	2.3	40
6	Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists?. <i>Arthritis Care and Research</i> , 2012 , 64, 455-8	4.7	13
5	Infliximab in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012 , 89, 71-3		7
4	Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S28-41	2.2	50
3	Psoriatic arthritis: a systematic review. <i>International Journal of Rheumatic Diseases</i> , 2010 , 13, 300-17	2.3	71
2	Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2009 , 1, 163-178	2.4	3
1	Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. <i>Arthritis and Rheumatism</i> , 2006 , 55, 812-6		37